Clarus Therapeutics Holdings, Inc. (CRXT): Price and Financial Metrics
GET POWR RATINGS... FREE!
CRXT Stock Price Chart Interactive Chart >
CRXT Price/Volume Stats
| Current price | $0.42 | 52-week high | $31.24 |
| Prev. close | $0.38 | 52-week low | $0.33 |
| Day low | $0.37 | Volume | 5,585,100 |
| Day high | $0.45 | Avg. volume | 8,393,801 |
| 50-day MA | $0.98 | Dividend yield | N/A |
| 200-day MA | $3.34 | Market Cap | 10.48M |
Clarus Therapeutics Holdings, Inc. (CRXT) Company Bio
Clarus Therapeutics Holdings, Inc. operates as a men's health specialty pharmaceutical company that focuses on the development and commercialization of oral testosterone replacement therapy in the United States. It offers JATENZO, a soft gel oral formulation of testosterone undecanoate for treating hypogonadal men. The company has a licensing agreement with HavaH Therapeutics for product to treat androgen-dependent inflammatory breast disease and certain forms of breast cancer. Clarus Therapeutics Holdings, Inc. was founded in 2003 and is based in Northbrook, Illinois.
Latest CRXT News From Around the Web
Below are the latest news stories about Clarus Therapeutics Holdings Inc that investors may wish to consider to help them evaluate CRXT as an investment opportunity.
Clarus Announces Strategic Partnerships for JATENZO® (testosterone undecanoate) with Vault Health and AssistRx – Leaders in Providing Healthcare Services to PatientsJATENZO is the first and only FDA-approved oral softgel capsule for testosterone replacement therapy in adult males who have deficient testosterone due to certain medical conditions New offerings underscore Clarus’ continued commitment to providing solutions for patients Partnership with Vault Health enables clinical care from the comfort of patients’ homes Partnership with AssistRx, the intelligent therapy initiation and patient support solutions provider, streamlines process for JATENZO prescr |
Maxim Group Thinks Clarus Therapeutics Holdings’ Stock is Going to RecoverIn a report issued on February 2, Naz Rahman from Maxim Group maintained a Buy rating on Clarus Therapeutics Holdings (CRXT – Research Report), with a price target of $4.00. The company's shares closed last Friday at $1.28, close to its 52-week low of $1.16. According to TipRanks.com, Rahman has 0 stars on 0-5 stars ranking scale with an average return of -38.8% and a 4.3% success rate. Rahman covers the Healthcare sector, focusing on stocks such as Vertex Pharmaceuticals, Galmed Pharmaceuticals, and Quoin Pharmaceuticals. Currently, the analyst consensus on Clarus Therapeutics Holdings is a Moderate Buy with an average price target of $8.00. |
Clarus Therapeutics Appoints Dr. Zhanna Jumadilova as Chief Clinical Development OfficerDr. Jumadilova most recently led clinical development programs at Insmed and Pfizer and has nearly 30 years of combined pharmaceutical and biotech experience NORTHBROOK, Ill., Jan. 18, 2022 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, Inc. (Clarus) (Nasdaq:CRXT), a pharmaceutical company dedicated to providing solutions to unmet medical needs by advancing androgen and metabolic therapies for men and women, today announced the appointment of Zhanna Jumadilova, M.D., M.B.A., as Chief Clinical |
Powell Investment Advisors, LLC Buys SVF Investment Corp, Meta Platforms Inc, Vanguard Large ...Investment company Powell Investment Advisors, LLC (Current Portfolio) buys SVF Investment Corp, Meta Platforms Inc, Vanguard Large Cap ETF, Bank of America Corp, Eli Lilly and Co, sells Financial Select Sector SPDR, ARK Innovation ETF, Unilever PLC, AMMO Inc, Apollo Global Management Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Powell Investment Advisors, LLC. |
Clarus Therapeutics Announces Closing of Approximately $15 Million Private PlacementProceeds to support the ongoing commercialization of JATENZO® (testosterone undecanoate) NORTHBROOK, Ill., Dec. 07, 2021 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, Inc. (Clarus) (Nasdaq:CRXT), a pharmaceutical company dedicated to providing solutions to unmet medical needs by advancing androgen and metabolic therapies for men and women, today announced that it has closed its previously announced definitive agreement to sell securities in a private placement with a leading healthcare inves |
CRXT Price Returns
| 1-mo | -43.24% |
| 3-mo | -55.41% |
| 6-mo | -91.94% |
| 1-year | -95.82% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -82.72% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
Loading social stream, please wait...